Seeking Alpha

Neurocrine Biosciences (NBIX) -2.8% AH after announcing a Phase II study for its NBI-98854 drug...

Neurocrine Biosciences (NBIX) -2.8% AH after announcing a Phase II study for its NBI-98854 drug for treating tardive dyskinesia failed to meet its primary endpoint, when a site featuring "inconsistent and incorrect application" of its assessment protocol was included. Without the site in question, the study showed a significant reduction in TD symptoms.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|